CLAIMS

1. A pharmaceutical composition comprising:

(a) glycopyrronium bromide at a dosage in the range of 0.5-100 μg per acutation; and

(b) formoterol or a salt thereof at a dosage in the range of 1-25 μg per acutation;

dissolved in an HFA propellant and a co-solvent, characterised in that said composition contains an amount of 1M HCl in the range 0.1 - 0.3 μg/μl.

2. A composition according to claim 1 wherein the range of 1M HCl is 0.15 - 0.28 μg/μl.

3. A pharmaceutical composition according to claim 1 or claim 2 wherein the co-solvent is ethanol.

4. A pharmaceutical composition according to any preceding claim further comprising one or more pharmaceutically active ingredients selected from the group consisting of beta-2 agonists, corticosteroids, antimuscarinic agents, and phosphodiesterase (IV) inhibitors.

5. A pharmaceutical composition according to claim 4 wherein the corticosteroid is beclometasone dipropionate.

6. A pharmaceutical composition according to any preceding claim wherein (a) glycopyrronium bromide is at a dosage in the range of 5-26 μg per acutation and (b) formoterol or a salt thereof is at a dosage in the range of 5-15 μg per acutation.

7. A pharmaceutical composition according to any preceding claim wherein (a) glycopyrronium bromide is at a dosage of 25 μg per acutation and (b) formoterol fumarate is at a dosage of 6 or 12 μg per acutation.

8. A pharmaceutical composition according to claim 5 wherein beclometasone dipropionate is at a dosage in the range of 50-250 μg per acutation.

9. A pharmaceutical composition according to any preceding claim which has been substantially purged of oxygen.

10. An aerosol canister comprising the pharmaceutical composition as defined in any preceding claim.

11. A canister according to claim 10 from which the headspace oxygen has been substantially removed.

12. A method of filling the canister as defined in claim 10 or claim 11 comprising the steps of:

(a) preparing a solution of glycopyrronium bromide, formoterol fumarate and optionally beclometasone dipropionate in a co-solvent to which 1M HCl has been added in an amount of 0.1 - 0.3 μg/μl of the final solution;

(b) filling the aerosol canister with said solution;

(c) placing the valve onto the can and (vacuum) crimping; and

(d) pressure-filling the container with HFA propellant through the valve.

13. A kit-of-parts comprising the pharmaceutical composition as defined in any of claims 1 to 9 and further comprising one or more pharmaceutically active ingredients for separate, sequential or simultaneous administration, wherein said pharmaceutically active ingredients are selected from the group consisting of beta

agonists, corticosteroids, antimuscarinic agents, and phosphodiesterase (IV) inhibitors.

14. A pharmaceutical composition according to any of claims 1 to 9 for use in the prevention or treatment of asthma and COPD.

~~15. Use of the pharmaceutical composition according to any of claims 1 to 9 in the manufacture of a medicament for the prevention or treatment of asthma and COPD.~~